

CURRICULUM VITAE

JOSE LUTZKY, MD, FACP

EDUCATION:

High School: Colegio Israelita Brasileiro

1968-1974 Porto Alegre, RS, Brazil

Medical School: Universidade Federal do Rio Grande do Sul (UFRGS)

1975-1980 Porto Alegre, RS, Brazil; December 1980

POSTGRADUATE TRAINING:

Residency: *Internal Medicine*

Universidade Federal do Rio Grande do Sul
University Hospital(Hospital das Clinicas)
Porto Alegre RS Brazil
January 1981-June 1982

Mount Sinai Medical Center
Miami Beach FL
PGY1-PGY3
July 1982-June 1985

Fellowship: *Hematology/Oncology*

Columbia-Presbyterian Medical Center
Columbia University College of Physicians and Surgeons
New York, NY
July 1985-June 1988

POSITIONS:

Assistant Attending Physician, Presbyterian Hospital, New York, NY. November 1987 to November 1988.
Staff Physician, Section of Hematology Oncology, Long Beach VAMC. December 1988-February 1991.
Attending Physician, University of California, Irvine Medical Center, March 1991-September 1994.
Director, Lymphoma/Myeloma Multidisciplinary Program, UC Irvine, July 1992-September 1994.
Associate Attending, Mount Sinai Cancer Center. Miami Beach, FL. October 1994 - present.
Associate: Nixon, Blaustein, Ratzan, P.A. October 1994 - October 1995.
Partner: Nixon, Blaustein, Ratzan, Lutzky, P.A. November 1995 - present.
Co-Director, Blood Stem Cell Transplantation Program, Mount Sinai Cancer Center, Miami Beach, FL. 1997 – 2000
Director, Melanoma Program, Mount Sinai Medical Center, Miami Beach, FL. 1997 - present.
Co-Director, Salick Research Department at Mount Sinai Cancer Center, FL. 2000 - 2002.
National Chair, Melanoma Committee, Salick Research Department. 2000 - 2002.
Co-Chief, Division of Hematology/Oncology, Mount Sinai Medical Center 2002 – present.
Co-PI, Mount Sinai CCOP 2002 – 2008.
Special Expert Witness, Agency for Health Care Administration, State of Florida, 1997 – 2007
Board of Directors, Florida Society of Clinical Oncology, 2008- present

ACADEMIC APPOINTMENTS

Instructor in Clinical Medicine; Columbia University College of Physicians and Surgeons, New York, NY.
November 1987 to November 1988.
Assistant Professor of Medicine, University of California, Irvine. December 1988- September 1994.
Clinical Assistant Professor of Medicine, University of Miami, Miami, Florida. September 1994 - 2009.

COMMITTEE PARTICIPATION/OTHER

Quality of Care Subcommittee: Long Beach VAMC, 1989-1991
Clinical Pertinence Committee: Long Beach VAMC, 1989-1991
Southwest Oncology Group: Leukemia, Lymphoma and Myeloma Committees, 1991-1994
Vice-Chair, UC Irvine Cancer Center Education Committee, July 1992-September 1994.
Clinical Protocol Review Committee: UC Irvine Cancer Center, 1992-1994
Human Subjects Committee: UC Irvine, 1992-1994
Medical Student Admissions Interview Committee: UC Irvine, 1992-1994
Human Rights Committee, Mount Sinai Medical Center, FL, 1994 - 1995
Research Committee, Mount Sinai Medical Center, FL, 1994 - 1997
Cancer Committee, Mount Sinai Medical Center, FL, 1995 - 2005
Chair, Cancer Research Committee, Mount Sinai Medical Center, 2010 - present
Continuing Medical Education Committee, Dade County Medical Association, FL, 1995 - 2000
Salicknet Quality of Care Committee, South Florida Region, 1997- 1999.
International Affairs Committee, Mount Sinai Hospital, 1997- 2001
IRB/Research Committee, Mount Sinai Hospital, 1997 - present
Member, CALGB Melanoma Working Group, 2003- 2006
Program Committee, Florida Society of Clinical Oncology, 2006- present
Program Committee Chairman, Florida Society of Clinical Oncology, 2009- present
Executive Committee, Florida Society of Clinical Oncology, 2009 - present
Executive Committee, Florida Cancer Trials Network, 2011- present.
ICORE/Magellan Healthcare, Oncology Coverage Guidelines Advisory Board, 2009- present
Reviewer, Cancer, 2006- present
Reviewer Journal of Clinical Oncology, 2011- present
Editorial Board, HemOnc Today, 2011- present.

AWARDS AND OTHER EDUCATIONAL ACTIVITIES:

1. Latin American Student Exchange Program: University of Miami: January-December 1980
2. American Cancer Society Audrey Myers Fellowship: January-December 1986
3. Upjohn Travel Award/American Association for Cancer Research: February 1988.
4. Lymphoma Research Foundation Fellowship - July 1993-July 1994
5. Fellow of the American College of Physicians – 1995

MEMBERSHIPS:

American College of Physicians
American Society of Clinical Oncology
American Society of Hematology
American Association for Cancer Research
International Society for Biological Therapy of Cancer
Society for Melanoma Research
Southern California Pharmacology Group, 1991-1994

CERTIFICATION:

E.C.F.M.G.- 1979
Visa Qualifying Examination-Sep 1981
Canadian Medical Council Evaluating Examination-Sep 1981
FLEX-Dec 1983
Diplomate of the American Board of Internal Medicine (ABIM)-Sep 1985
ABIM-Certification in Medical Oncology-Nov 1987
ABIM- Certification in Hematology-Nov 1988

BIBLIOGRAPHY:

a. Published articles:

1. J. Lutzky, M. Astor, R. N. Taub, M. A. Baker, K. Bhalla, J. E. Gervasoni, Jr.; A. Hindenburg. Role of glutathione and dependent enzymes in anthracycline resistant HL60/AR cells. *Cancer Res* 49:4120-4125, 1989.
2. A. A. Hindenburg, J. E. Gervasoni, V. Stewart, S. Krishna, J. Lutzky, K. Bhalla, R. N. Taub. Intracellular distribution and pharmacokinetics of daunorubicin in anthracycline sensitive and resistant HL60 cells. *Cancer Res* 49:4607-4614, 1989.
3. K. Bhalla, M. Birkhofer, Z. Arlin, S. Grant, J. Lutzky, and G. Graham. Effect of rGM-CSF on the metabolism of cytosine arabinoside in normal and leukemic bone marrow cells. *Leukemia* 2(12): 810-813, 1988.
4. M. B. Cohen, J. H. M. Austin, A. Smith-Vaniz, J. Lutzky, and M. Grimes. Nodular bleomycin toxicity. *Am J ClinPathol* 92:101-104, 1989.
5. J. E. Gervasoni, R. N. Taub, M. Rosado, V. Stewart, S. Krishna, W. Ross, M. A. Baker, K. Bhalla, J. Lutzky, A. Hindenburg. Membrane glycoprotein changes associated with anthracycline resistance in HL60 cells. *Cancer Chemother Pharmacol* 28: 93-101, 1991.
6. K. Bhalla, M. Birkhofer, Z. Arlin, S. Grant, J. Lutzky, H. Safah, G. Graham. Differential effect of IL-3 on the metabolism of high dose cytosine arabinoside in normal versus leukemic human bone marrow cells. *Exp Hematol* 19: 669-672, 1991.
7. K. Bhalla, M. Birkhofer, M. Bhalla, J. Lutzky, A. Hindenburg, J. Cole, C. Ince. Phase I study of a combination of allopurinol, 5-fluouracil and leucovorin followed by hydroxyurea in patients with advanced gastrointestinal

malignancies and breast cancer. *Am J Clin Oncol* 14(6): 509-13, 1991.

8. K. Bhalla, C. Holladay, J. Lutzky, A.M. Ibrado, G. Bullock, M. Jasiok, and S. Singh. Deoxycytidine protects normal bone marrow progenitors against Ara-C and gemcitabine cytotoxicity without compromising their activity against cisplatin-resistant human ovarian cancer cells. *Gynecol Oncol* 45,32-39, 1992.

9. K. Bhalla, G. Bullock, J. Lutzky, C. Holladay, A.M. Ibrado, M. Jasiok, S. Singh Effect of combined treatment with interleukin-3 and interleukin-6 on 4-hydroperoxycyclophosphamide-mediated reduction of glutathione levels and cytotoxicity in normal and leukemic bone marrow progenitor cells. *Leukemia* Aug, 6(8):814-819, 1992.

10. J.E. Gervasoni, Jr., R.N. Taub, M.T. Yu, D. Warburton, M. Sabbath, D. Coppock, J. D'Alessandri, S. Krishna, M. Rosado, M.A. Baker, J. Lutzky, E.R. Chanda, J.H. Gerlach, M.J. Pinkoski, S.P.C. Cole and A.A. Hindenburg. Homogeneously staining region in anthracycline resistant HL60/AR cells not associated with MDR1 amplification. *Cancer Res* 52: 5244-5249, 1992.

11. M. Samoszuk, A. Anderson, E. Ramzi, F. Wang, P. Braunstein, H. Majmundar, J. Lutzky and L.M. Slater. Radioimmuno-detection of Hodgkin's disease and non-Hodgkin's lymphomas with monoclonal antibody to eosinophil peroxidase. *J Nucl Med* 34: 1246-1253, 1993.

12. G. Bullock, C. Tang, E. Tourkina, A. M. Ibrado, J. Lutzky, Y. Huang, M.E. Mahoney and K. Bhalla. Effect of combined treatment with interleukin-3 and interleukin-6 on 4-hydroperoxycyclophosphamide-induced programmed cell death or apoptosis in human myeloid leukemia. *Exp Hematol* 21:1640-7, 1993.

13. J. Cho, Y. Lee, J. Lutzky, L. Redpath, L. Slater. Collateral sensitivity to cisplatin and radiation in a multidrug resistant human leukemia cell line. *Cancer Chemother Pharmacol*, 1996.

14. RC Lilenbaum, MA Schwartz, R Cano, E Krill, J Lutzky, A Blaustein, L Seigel, M. Viales, CJ, Dominguez and E. Davila. Gemcitabine and navelbine in advanced non-small cell lung cancer. *Cancer* 88:557-62, 2000.

15. K.A. Foon, J. Lutzky, L. Hutchins, O. Kashala, J. Garrison, R.A. Reisfeld, A. Teitelbaum, M. Chatterjee. Clinical and immune responses in melanoma patients immunized with an anti-idiotypic (ID) antibody mimicking GD2. *J Clin Oncol* 18:376-384, 2000.

16. P. Scheinberg and J. Lutzky. O tratamento adjuvante do melanoma maligno. *SBOC Revista* 1:51-62, 2000.

17. J. Lutzky, A.M. Gonzalez-Angulo and J. Orzano. Antibody-based vaccines for the treatment of melanoma. *Semin Oncol* 29(5):462-70, 2002.

18. S. Jagannath, BJ Durie, J. Wolf, E. Camacho, D. Irwin, J. Lutzky, M. McKinley, E. Gabayan, M. Mazumder, D. Schenkein, J. Crowley. Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma. *Br J Haematol*. 129(6):776-83, 2005

19. J.B. Alexis, A.E. Martinez and J. Lutzky. An immunohistochemical evaluation of c-kit (CD-117) expression in malignant melanoma, and results of imatinib mesylate (Gleevec) therapy in three patients. *Melanoma Res*. 15(4):283-5, 2005.

20. KD Lewis, JA Thompson, JS Weber, WA Robinson, S O'Day, J Lutzky, SS Legha, S Floret, F Ruvuna, R Gonzalez. A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma. *Invest New Drugs*.24(1):89-94, 2006.

21. J R Berenson, R Boccia, D Siegel, M Bozdech, A Bessudo, E Stadtmauer, J Talisman Pomeroy, R Steis, M

- Flamm, J Lutzky, S Jilani, J Volk, SF Wong, R Moss, R Patel, D Ferreti, K Russell, R Louie, HS Yeh and RA Swift. Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicenter, phase II, single-arm study. *Br J Haematol.* 135(2): 174-83, 2006.
22. A Testori, J Richards, E Whitman, GB Mann , J Lutzky, L Camacho, G Parmiani, G Tosti, J Kirkwood, A Hoos, L Yuh, R Gupta and PK Srivastava . Phase III comparison of Vitespen, an autologous tumor-derived heat shock protein gp96 peptide complex vaccine, with physician's choice of treatment for stage IV melanoma: the C-100-21 study group. *J Clin Oncol* 26(6): 956-962, 2008.
23. J Lutzky, J Bauer , BC Bastian . Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation. *Pigment Cell Melanoma Res.* 21(4):492-3, 2008.
24. RL Johnston , J Lutzky, A Chodhry, JS Barkin. Cytotoxic T-Lymphocyte-Associated Antigen 4 Antibody-Induced Colitis and Its Management with Infliximab. *Dig Dis Sci.* Nov;54(11):2538-40, 2009.
25. J Lutzky, R Weber, Y Nunez, M Gillett, L Spitler. A phase 1 study of granulocyte macrophage colony-stimulating factor (sargramostim) and escalating doses of thalidomide in patients with high-risk malignant melanoma. *Journal of Immunotherapy.* 32(1):79-85, 2009
26. S. O'Day, M. Atkins, J. Weber, J. Thompson, C. Anderson, R. Gonzalez, J. Lutzky, T. Amatruda, E. Hersh, P. Boasberg. A phase II multi-center trial of maintenance biotherapy (MBT) after induction concurrent biochemotherapy (BCT) for patients (Pts) with metastatic melanoma (MM). *J Clin Oncol.* Dec 20;27(36):6207-12, 2009.
27. S Jagannath, BGM Durie, JL Wolf, ES Camacho, D Irwin, J Lutzky, M McKinley, P Potts, AE Gabayan, A Mazumder, J Crowley and R Vescio. Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. *Br J Haematol.* Sep;146(6):619-26, 2009.
28. J Wolchok, B Neyns, G Linette, S Negrier, J Lutzky, L Thomas, W Waterfield, D Schadendorf, M Smylie, T Guthrie, Jr., Grob, J Chesney, K Chin, J Li, A Hoos, SJ O'Day*, and C Lebbé. Ipilimumab monotherapy in patients with previously treated unresectable stage III or stage IV melanoma: results from a randomized, double-blind, multicenter, phase dose-ranging study. *Lancet Oncol.* Feb;11(2):155-64, 2010.
29. K Koyanagi , SJ O'Day, P Boasberg , MB Atkins , HJ Wang, RGonzalez , K Lewis , JA Thompson , CM Anderson, J Lutzky, TT Amatruda, E Hersh, JM Richards, JS Weber and D Hoon. Serial monitoring of circulating tumor cells predict outcome of induction biochemotherapy plus maintenance biotherapy for metastatic melanoma. *Clin Cancer Res.* Apr 15;16(8):2402-8, 2010.
30. H Soares and J Lutzky. Drug evaluations: Velimogene aliplasimid. *Expert Opinion Biological Therapy Expert Opin Biol Ther.* May;10(5):841-51, 2010.
31. 2. FS Hodi, SJ O'Day, D McDermott, RW Weber, JA Sosman, JB Haanen, R Gonzalez, C Robert, J Hassel, W Akerley, AJM van den Eertwegh, J Lutzky, P Lorigan, J Vaubel, G Linette, D Hogg, CH Ottensmeier, C Lebbé, C Peschel, I Quidt, J Clark, J Wolchok, J Weber, J Tian, M Yellin, GM Nichol, A Hoos and W Urba. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma. *N Engl J Med.* Aug 19;363(8):711-23, 2010.
32. J Lutzky. New therapeutic options in the medical management of advanced melanoma. *Semin Cutan Med Surg.* Dec;29(4):249-57, 2010.
33. RD Carvajal, CR Antonescu, JD Wolchok, PB Chapman, R Roman, J Teitcher, KS Panageas , KJ Busam , B Chmielowski, J Lutzky, AC Pavlick, A Fusco, L Cane, N Takebe, S Vemula, N Bouvier, BC Bastian, and GK Schwartz. KIT as a therapeutic target in metastatic melanoma. Submitted for publication, *JAMA* 305(22):2327-34, 2011.
34. JP Fruehauf, J Lutzky, DF McDermott, CK Brown, JB Meric, B Rosbrook, DR Shalinsky, KF Liaw, AG

Niethammer, S Kim, O Rixe. Multicenter, phase II study of axitinib, a selective second-generation inhibitor of vascular endothelial growth factor receptors 1, 2, 3 in patients with metastatic melanoma. Clin Cancer Res. 2011 Oct 5. [Epub ahead of print].

b. Manuscripts in preparation/submitted

1. J.Lutzky, A. Gonçalves, Y. Nunez, S. Bowling. A Phase I study of arsenic trioxide plus dacarbazine in malignant melanoma. Manuscript in preparation.

2. J. Lutzky, Y. Nunez, P. Graham. A Phase II study of oxaliplatin in patients with Stage IV melanoma. Manuscript in preparation.

3. J Lutzky, DH Lawson, Y Enriquez-Nunez, D Gabrilovich. Phase II trial of high-dose IL-2 with priming and concomitant sargramostim in patients with advanced melanoma. Manuscript in preparation.

4. J Lutzky, O Hamid, Y Enriquez-Nunez and S O'Day. Phase II trial of carboplatin, ABI-007 and sorafenib in patients with metastatic melanoma. Manuscript in preparation.

c. Abstracts:

1. J. Lutzky, M. Astor, R. N. Taub, M. A. Baker, A. Hindenburg. Anthracycline resistance in leukemia: role of glutathione. [abstract] Blood 70(5)suppl. 1, 234a, 1987.

2. J. Lutzky, M. B. Astor, R. N. Taub, M. A. Baker, A. Hindenburg. Glutathione localization: relation to anthracycline resistance in human leukemic HL60 and KG1 cell lines[abstract]. Proc AACR 29:1882, 1988.

3. J. Lutzky, M. B. Astor, R. N. Taub, E.J. Hall, M. A. Baker, A. Hindenburg. Distribution of intracellular glutathione and anthracycline resistance [abstract]. Presented at the VIth International Meeting on Chemical Modifiers of Cancer Treatment. Paris, France, March 21-25, 1988.

4. M. B. Astor, J. Lutzky, A. Hindenburg, E. J. Hall, and R. N. Taub. Distribution of intracellular glutathione as determined using digitized video fluorescence microscopy and monochlorobimane [abstract]. Presented at the VIth International Meeting on Chemical Modifiers of Cancer Treatment. Paris, France, March 21-25, 1988.

5. K. Bhalla, M. Birkhofer, Z. Arlin, S. Grant, J. Lutzky, and G. Graham. Effect of rGM-CSF and IL3 on the metabolism of cytosine arabinoside in normal and leukemic human bone marrow cells. [abstract] Blood 72(5)suppl1,1988.

6. J. Lutzky, V. J. Stewart, S. Krishna, M. Rosado, J. E. Gervasoni, Jr., R. N. Taub, M. A. Baker and A. A. Hindenburg. Multifactorial mechanisms of anthracycline resistance in human melanoma cell lines. Proc AACR 30:2034, 1989.

7. R. A. Remnick; J. E. Gervasoni, Jr., A. A. Hindenburg, J. Lutzky, S. Krishna, M. Rosado, and R. N. Taub. The subcellular distribution of daunorubicin in drug resistant cell lines that do and do not overexpress the P-glycoprotein. Proc AACR 30:2032, 1989.

8. J. E. Gervasoni, Jr., R. N. Taub, M. Rosado, S. Krishna, J. Lutzky, M. A. Baker, and A.A. Hindenburg. Surface membrane glycoprotein alterations associated with multidrug resistance in a P-glycoprotein negative cell line. Proc AACR 30: 2032, 1989.

9. J. E. Gervasoni, Jr., D. Warburton, M. Rosado, S. Krishna, J. Lutzky, R. A. Remnick, M. A. Baker, A. A. Hindenburg and R. N. Taub. Identification of a homogeneously staining region on chromosome 7 at position q11.2

in an anthracycline resistant cell line that does not overexpress the P-glycoprotein. Proc AACR 30;2013, 1989.

10. A. A. Hindenburg, J. E. Gervasoni, Jr., J. Lutzky, S. Krishna, M. Rosado, R. A. Remnick, M.A. Baker and R.N. Taub. Characterization of drug efflux in a multidrug resistant cell line that does not overexpress the P-glycoprotein. Proc AACR 30:2033, 1989.

11. K. Bhalla, M. Birkhofer, M. Baker, J. Cole, J. Lutzky and S. Grant. Phase I and pharmacologic study of continuous infusion high dose Ara-C and deoxycytidine in refractory leukemia and lymphoma. Blood 74(7) suppl1: 156a, 1989.

12. K. Bhalla, M. Kommor, S. Grant and J. Lutzky. Improved selectivity of ara-C against AML blasts by a combined treatment with rGM-CSF and r-IL3. Proc AACR 31:2505,1990.

13. G. Bullock, J. Lutzky, C. Holladay, M. Jasiok, K. Madrid, and K. Bhalla. The effect of rIL-3 and r GM-CSF on glutathione and glutathione transferase in normal human bone marrow cells and leukemic blasts. Blood 76, 1990.

14. J. Cho, Y. Lee, J. Lutzky, M. Stupecky, P. Sweet, L. Redpath, L. Slater. Collateral sensitivity to cisplatin and radiation in a multidrug resistant human leukemia cell line. Proc AACR 32, 1991.

15. J. Lutzky, K. K. Madrid, S. Krishna, K. Bhalla, A. A. Hindenburg and Taub, R. N. Effect of glutathione depletion plus verapamil on HL60 and HL60/AR cells. Proc AACR 32, 1991.

16. G. Bullock, C. Holladay, J. Lutzky, M. Jasiok, A.M. Ibrado, and K. Bhalla. Effect of rIL-6 plus rIL-3 on glutathione (GSH)/GSH-S-transferase (GST) in leukemic blasts versus normal bone marrow cells. Proc AACR 32, 1991.

17. G. Bullock, C. Holladay, A.M. Ibrado, J. Lutzky, M. Jasiok, E. Tourkina, M.E. Mahoney, D. Dane and K. Bhalla. The effect of IL-3 and IL-6 on 4-hydroxycyclophosphamide(4-HC) mediated programmed cell death (PCD) in human leukemic cells. Blood 78, 1991.

18. J. Lutzky; A. L. Canada; D. T. Yamanishi; K. Bhalla and A. A. Hindenburg. Effect of verapamil and buthionine sulfoximine (BSO) on daunorubicin (DNR) cytotoxicity of multidrug-resistant human melanoma cell lines overexpressing P-glycoprotein and glutathione-S-transferases. Proc AACR 33, 1992.

19. J. Lutzky, M. Vujicic, D.T. Yamanishi and K. Bhalla. Antiproliferative effects of all-trans retinoic acid (tRA) and 9-cis retinoic acid (9-cisRA) on human lymphoid cell lines. Proc AACR 34, 1993.

20. J.K. Bleiler, C. Tang, J. Lutzky, M.E. Mahoney, Y.Huang and K. Bhalla. Taxol induced apoptosis in human myeloma cells. Blood 82, 1993.

21. J. Lutzky, M. Vujicic, L. Binderup and K. Bhalla. Vitamin D analogs and retinoids exhibit additive cytotoxicity to human myeloma cell lines. Proc AACR, 35, 1994.

22. M. Krishna, J. Gervasoni, J. Lutzky, R.N. Taub and A.A. Hindenburg. Translocation between chromosomes 7 and 16 in mdr HL60 cells. International Conference on Drug Resistance; St. Gallen, Switzerland, September 1994.

23. J. Atiba, A Manzardo, M Schell, R Thiruvengadam, J Prestifilippo, J Lutzky. Restoration of oral all-trans-retinoic acid (tRA) bioavailability: combination therapy with alpha interferon (Ifn) versus a drug holiday. Proc Annu Meet Am Soc Clin Oncol (1995) 14:A1484, 1995.

24. RC Lilenbaum, MA Schwartz, R Cano, E Krill, J Lutzky, A Blaustein, L Seigel, M. Viales, CJ Dominguez and E. Davila. Gemcitabine and navelbine in advanced non-small cell lung cancer. Proc Annu Meet Am Soc Clin Oncol (1998), 17: A1901, 1998.

25. K.A. Foon, J. Lutzky, L. Hutchins, O. Kashala, J. Garrison, R.A. Reisfeld, A. Teitelbaum, M. Chatterjee. Clinical and Immune Responses in Melanoma Patients Immunized with an Anti-Idiotypic (ID) Antibody Mimicking GD2.

Proc Annu Meet Am Soc Clin Oncol (1999) 18: A1672, 1999.

26. M. B. Atkins, J. Bearden, R. Blum, R. DeConti, R. Gonzalez, L. Hutchins, J. Lutzky, J. Nemunaitis, J. Rubin, P. Schwarzenberger, D. Gillespie, L. Selk. Phase II trial of HLA-B7 plasmid DNA/lipid (Allovectin-7) immunotherapy in patients with metastatic melanoma. Proc Annu Meet Am Soc Clin Oncol (2000) 19: A1801, 2000.

27. M Chatterjee, J Lutzky, M Safa, J Sussman, V Bard, R Baral, R Das, A Saha, R Shukla, R Reisfeld, L Hutchins, A Bhatnagar, KA Foon . Immune and clinical comparison of different adjuvants combined with Trigem: an anti-idiotypic (anti-id) monoclonal antibody (mab) treatment for stage III melanoma. Proc Annu Meet Am Soc Clin Oncol (2001)

28. M Safa, M Chatterjee, J Lutzky, J Sussman, V Bard, R Baral, R Das, A Saha, R Shukla, R Reisfeld, L Hutchins, A Bhatnagar, KA Foon. Trigem anti-idiotypic (anti-id) monoclonal antibody (mab) treatment for stage III melanoma: results of a multicenter phase II trial. Proc Annu Meet Am Soc Clin Oncol (2001)

29. J Lutzky, A Blaustein, D Weingrad, J Lobracco, E Kruglyak, A Koletsky. Phase I/II study of GM-CSF and thalidomide in patients with high-risk malignant melanoma. Proc Annu Meet Am Soc Clin Oncol (2003).

30. J. Richards, A. Y. Bedikian, R. Gonzalez, M. B. Atkins, E. D. Whitman, J. Lutzky, M. A. Morse, T. Amatruda, E. Galanis. A phase 2 trial of high-dose Allovectin-7 in patients with advanced metastatic melanoma. Proc Annu Meet Am Soc Clin Oncol (2004)

31. S. Jagannath, B. Durie, J. Wolf, E. Camacho, D. Irwin, J. Lutzky, M. McKinley, E. Gabayan, J. Crowley, D. P. Schenkein. First-line therapy with bortezomib (formerly PS-341) in patients with multiple myeloma (MM). Proc Annu Meet Am Soc Clin Oncol (2004)

32. J.M. Richards, A. Bedikian, R. Gonzalez, M. B. Atkins, E. Whitman, J. Lutzky, M. A. Morse, T. Amatruda, E. Galanis, J. Thompson. High-dose Allovectin-7 in patients with advanced metastatic melanoma: final Phase 2 data and design of Phase 3 registration trial. Proc Annu Meet Am Soc Clin Oncol (2005)

33. S. O'Day, M. Atkins, J. Weber, J. Thompson, C. Anderson, R. Gonzalez, J. Lutzky, T. Amatruda, E. Hersh, P. Boasberg. A phase II multi-center trial of maintenance biotherapy (MBT) after induction concurrent biochemotherapy (BCT) for patients (Pts) with metastatic melanoma (MM). Proc Annu Meet Am Soc Clin Oncol (2005)

34. J. Lutzky, R. Weber, Y. Nunez, M. Menendez, M. Rose, S. Trautvetter, M. Timmerman, L. E. Spitler. A phase I study of granulocyte macrophage colony-stimulating factor (GM-CSF) and escalating doses of thalidomide in patients with high-risk malignant melanoma. Proc Annu Meet Am Soc Clin Oncol (2005)

35. J. Lutzky, Y. Nunez, S. Bowling. A Phase I study of arsenic trioxide plus dacarbazine in malignant melanoma. 6th World Congress on Melanoma, Vancouver, 2005, P-155.

36. S. Jagannath, B. Durie, J. Wolf, E. Camacho, D. Irwin, J. Lutzky, M. McKinley, E. Gabayan, A. Mazumder, J. Crowley, R. Vescio and D. Schenkein. Bortezomib therapy alone and in combination with dexamethasone for patients with previously untreated multiple myeloma. Blood (ASH Annual Meeting Abstracts)106:783, 2005.

37. J Berenson, R Boccia, D Siegel, M Bozdech, A Bessudo, E Stadtmauer, J Talisman Pomeroy, R Steis, M Flamm, J Lutzky, S Jilani, J Volk, T Lindgren, R Moss, R Patel, D Ferreti, H Yeh and S Bevivino. A multicenter phase II study of combination treatment with melphalan, arsenic trioxide and vitamin C (MAC) for patients with relapsed or refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts) 106: 2564, 2005.

38. J Lutzky, Y Nunez and P Graham. A phase II trial of oxaliplatin in patients with advanced melanoma. Proc Annu

Meet Am Soc Clin Oncol (2006).

39. J Richards, A. Testori, E Whitman, GB Mann, J Lutzky, L Camacho, G Parmiani, A Hoos, R Gupta, PK Srivastava. Autologous tumor-derived HSPPC-96 vs. physician's choice (PC) in a randomized phase III trial in stage IV melanoma. Proc Annu Meet Am Soc Clin Oncol (2006).

40. S Jagannath, B Durie, J Wolf, E Camacho, D Irwin, J Lutzky, M McKinley, A. Gabayan, A Mazumder, J Crowley and R Vescio. Long-term follow-up of patients treated with bortezomib alone and in combination with dexamethasone as frontline therapy for multiple myeloma (MM). Blood (ASH Annual Meeting Abstracts), 2006.

41. J Fruehauf, J Lutzky, D McDermott, CK Brown, Y Pithavala, PW Bycott, D Shalinsky, KF Liao, A Niethammer, O Rixe. Axitinib (AG-013736) in patients with metastatic melanoma: a phase II study. Proc Annu Meet Am Soc Clin Oncol (2008).

42. D Schadendorf, J Wolchok, C Lebbe, B Neyns, G Linette, S Negrier, J Lutzky, L Thomas, W Waterfield, M Smylie¹, T Guthrie Jr. , K Chin, R Ibrahim, A Hoos, J Grob. Association between lactate dehydrogenase levels and disease control and survival in ipilimumab-treated patients with advanced melanoma. Perspectives in Melanoma XII, Oct. 2008, poster P-073.

43. J Lutzky, Y Nunez, R Deck, S O'Day, O Hamid. First-stage results of a phase II study of carboplatin, nab-paclitaxel and sorafenib in patients with advanced melanoma. Abstract. Presented at the World Melanoma Congress, Vienna , Austria, May 2009.

44. D. Carvajal, P. B. Chapman, J. D. Wolchok, L. Cane, J. B. Teitcher, J. Lutzky, A. C. Pavlick, B. C. Bastian, C. Antonescu, G. K. Schwartz. A phase II study of Imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of *KIT*. Proc Annu Meet Am Soc Clin Oncol (2009).

45. J. Lutzky, J. Wolchok, O. Hamid, C. Lebbe, H. Pehamberger, G. Linette, V. de Pril, R. Ibrahim, A. Hoos, S. O'Day. Association between immune-related adverse events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three Phase II clinical trials. Proc Annu Meet Am Soc Clin Oncol (2009).

46. J Lutzky, DH Lawson, Y Enriquez-Nunez, D Gabrilovich. Phase II trial of high-dose IL-2 with priming and concomitant sargramostim in patients with advanced melanoma. Proc Annu Meet Am Soc Clin Oncol (2010).

47. P Schoffski , M Sgroi, H Burris, J Lutzky, T Rearden, B Sikic, J Stephenson, D Elhardt, Y Lee and R Kurzrock. Phase 2 randomized discontinuation trial (RDT) of XL184 (BMS-907351) in patients (Pts) with advanced solid tumors. Presented at the EORTC annual meeting, Berlin, Germany, 2010.

48. P Lorigan, JA Sossman, J Haanen, J Lutzky, D Hogg, M Gore, W Urba, V de Pril, R Ibrahim and J Wolchok. Clinical response to ipilimumab: effect of systemic corticosteroids used to manage immune-related adverse events. Poster 1331-P, presented at the 35th Annual ESMO Congress, Milan, Italy, Oct 2010.

49. CH Ottensmeier, RW Weber, JB Haanen, C Robert, D Schadendorf, J Lutzky, C Peschel, M Messina, R Ibrahim, and SJ O'Day. Ipilimumab produces durable objective responses in patients with previously treated, advanced melanoma: results from a phase II trial. Poster 1326-P, presented at the 35th Annual ESMO Congress, Milan, Italy, Oct 2010.

c. Letters to the editor:

1. K. Bhalla, M. Birkhofer, J. Lutzky. [letter to the editor] N Engl J Med 318(18):1227, 1988.